IFNA1 and infection: Among these papers, there were 926 cases treated with daclatasvir in combination with peg-IFN-α/RBV (daclatasvir group) and 174 cases treated with peg-IFN-α/RBV (control group) and they were infected with HCV genotype 1–4 infection with the genotype 1 infection accounting for 73.1 %, published from 2012 to 2015.